Send to

Choose Destination
Memo. 2016;9:82-84. Epub 2016 Jun 2.

Immune checkpoint blockade in ovarian cancer.

Author information

3rd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute (SCRI), Muellner Hauptstraße 48, 5020 Salzburg, Austria.


Increased numbers of tumour infiltrating T‑cells have long been associated with a better prognosis in ovarian cancer, which has led to the general assumption of a relevant impact of T‑cellular anti-tumour immunity in this disease. As a consequence of this knowledge, a multitude of immunologic therapies has emerged over the past years. Although some reports could evidence a successful induction of anti-tumour T‑cells, in general, these attempts did not translate into clinically significant activity. As has already been shown in other tumour entities, immune checkpoint blockade - mainly antibodies directed against PD-1 and PD-L1 - could possibly become a real "game changer" in ovarian cancer in the future.


Immune checkpoint; Immunotherapy; Ovarian cancer; PD-1; PD-L1

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center